• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. COR

Cencora, Inc.(COR)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Distribution
Cencora, Inc. logo

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Latest News & Analysis

Female healthcare executive in modern office with digital abstract visuals on purple background
Jun 12, 2025

Cencora's Strategic Growth: Specialty Drugs Drive Revenue Surge

Cencora's Q2 fiscal 2025 revenue surged +10.3%, fueled by specialty drugs. New board appointment strengthens supply chain as company navigates margin pressures.

Read more →
Graphic illustrating Cencora (COR) financial performance, showing strong revenue growth contrasted with declining net income and margins, reflecting strategic shifts in the healthcare distribution industry.
Jun 5, 2025

Cencora ([COR](/dashboard/companies/COR)) Financial Analysis: Revenue Growth vs. Margin Pressure

Cencora ([COR](/dashboard/companies/COR)) navigates strategic shifts, including international exploration and governance enhancements, against a backdrop of robust revenue growth tempered by margin pressures.

Read more →
Financial analysis and stock valuation of Cencora (COR), covering cash flow divergence, the impact of tariffs on the healthcare supply chain, and competitive dynamics.
Apr 21, 2025

Cencora (COR): Analyzing Tariff Headwinds and Cash Flow Dynamics

Deep dive into Cencora's recent developments, including tariff impacts, cash flow dynamics, competitive positioning, and analyst sentiment ahead of its Q2 earnings.

Read more →
Cencora (COR) stock soars to new heights: An in-depth analysis of the pharmaceutical leader's strategic growth and market resilience.
Apr 9, 2025

Cencora (COR): Riding All-Time Highs Amidst Market Volatility

Cencora (COR) reaches an all-time high amid market volatility, driven by strategic AI adoption, tariff mitigation, and strong financials. Q2 Fiscal 2025 earnings are eagerly awaited.

Read more →
Cencora Q2 2025 Earnings Preview: Analysis of growth, AI integration, and financial risks for investors. #Cencora #Earnings #AI #Healthcare
Apr 2, 2025

Cencora (COR): Q2 Earnings Preview, AI Impact, and Growth

Comprehensive analysis of Cencora (COR) focusing on Q2 2025 earnings, AI initiatives, financial sustainability, and market strategies.

Read more →
Cencora (COR) stock analysis: financial performance, growth drivers, acquisitions, and investment outlook in the healthcare sector.
Mar 19, 2025

Cencora (COR) Analysis: Financials, Acquisitions, Market Outlook

In-depth analysis of Cencora (COR): financial performance, strategic acquisitions, and market outlook. Walgreens' stake reduction, RCA deal, and cash conversion cycle.

Read more →
Cencora (COR) stock analysis: growth, Walgreens stake, market trends, and investment outlook.
Mar 10, 2025

Cencora (COR): Financial Analysis of Growth and Market Trends

Analysis of Cencora's (COR) stock performance, financial results, Walgreens' reduced stake, and the RCA acquisition. Assesses competitive landscape, valuation, and future outlook.

Read more →
Cencora (COR) stock analysis: Navigating changes, stake reduction, financial health, strategic growth, and market outlook for investors.
Feb 28, 2025

Cencora (COR): Navigating Change and Charting Future Growth

Cencora (COR) is navigating change as Walgreens reduces its stake. Strong financials, strategic acquisitions, and share repurchases position it for growth.

Read more →
Cencora (COR) analysis: Walgreens' stake reduction, Q1 2025 earnings, and strategic outlook in pharmaceutical distribution.
Feb 27, 2025

Cencora (COR): Navigating Walgreens' Stake Reduction and Q1 2025 Performance

Analysis of Cencora's (COR) recent developments, including Walgreens' stake reduction, Q1 2025 earnings, and strategic acquisitions. Explores the company's outlook and key success factors.

Read more →
Cencora (COR) Stock Analysis: Walgreens Stake Reduction, Analyst Forecasts, and Q1 2025 Performance Insights
Feb 24, 2025

Cencora (COR): Walgreens' Stake Reduction, Analyst Outlook & Q1 2025 Analysis

Cencora's (COR) latest developments, including Walgreens' stake reduction, analyst outlook, and Q1 2025 earnings. Impact on financial health and growth prospects is analyzed.

Read more →
Cencora's strategic initiatives and Q1 2025 performance analysis, including share repurchase and growth in pharmaceutical distribution.
Feb 21, 2025

Cencora: Navigating Market Shifts and Industry Trends in 2025

A detailed analysis of Cencora's Q1 2025 earnings, share repurchase, and strategic positioning amid Walgreens' stake sale.

Read more →
Cencora's strategic shift: Analyzing specialty drug demand, Walgreens stake reduction, and financial performance. A deep dive into COR stock.
Feb 21, 2025

Cencora's Strategic Shift: Navigating Drug Demand and Stake Reduction

Cencora navigates specialty drug demand and Walgreens' stake reduction. Q1 earnings, strategic shifts, and market dynamics analyzed for investors and analysts.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.